ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma-Reference-Cited by-同舟云学术

ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma

Published:2022-05-09 Issue:8 Volume:29 Page:5020-5021
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Ono Masato,Nakamura Toru,Mizukami Yusuke,Hirano Satoshi

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-11735-6.pdf

Reference6 articles.

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.

2. Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.

3. Hayashi H, Kohno T, Ueno H, et al. Utility of assessing the number of mutated KRAS, CDKN2A, TP53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer. Pancreas. 2017;46(3):335–40.

4. Ono M, Ono Y, Nakamura T, et al. Predictors of long-term survival in pancreatic ductal adenocarcinoma after pancreatectomy: TP53 and SMAD4 mutation scoring in combination with CA19-9. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-11630-0

5. Nakamura T, Asano T, Okamura K, et al. A preoperative prognostic scoring system to predict prognosis for resectable pancreatic cancer: who will benefit from upfront surgery? J Gastrointest Surg. 2019;23(5):990–6.